The Microbiome and the Liver: The Basics

 

 Buy Article Permissions and Reprints

Abstract

The relationships between the microbiota and other aspects of normal human biology continue to be explored. Indeed, the volume of information relating to the interplay between the host and the microbiota has grown exponentially—especially with the advent of ever-improving techniques for rapidly sequencing and identifying bacterial populations and their functions. The gut is initially sterile at birth and colonization and dynamic changes occur during infancy and early childhood in order to establish a mature microbiome. The mature microbiome has direct and important interactions with host metabolism. Bacterial translocation from the gut microbiome is thought to be a key driver of inflammation in liver disease and changes in tolerance to these bacteria drive inflammation in the liver and elsewhere in the host. As we are better able to describe the composition and functional properties of the microbiome, the range of its impact on the homeostatic functions of the human body and implications for disease continue to be extended.

• References

• 1 Haque TR, Barritt IV AS. Intestinal microbiota in liver disease. Best Pract Res Clin Gastroenterol 2016; 30 (1) 133-142
  PubMedGoogle Scholar
• 2 Marques TM, Wall R, Ross RP, Fitzgerald GF, Ryan CA, Stanton C. Programming infant gut microbiota: influence of dietary and environmental factors. Curr Opin Biotechnol 2010; 21 (2) 149-156
  CrossrefPubMedGoogle Scholar
• 3 Bäckhed F. Programming of host metabolism by the gut microbiota. Ann Nutr Metab 2011; 58 (Suppl. 02) 44-52
  CrossrefPubMedGoogle Scholar
• 4 Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science 2005; 307 (5717) 1915-1920
  CrossrefPubMedGoogle Scholar
• 5 Lv LX, Fang DQ, Shi D , et al. Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis. Environ Microbiol 2016; 18 (7) 2272-2286
  CrossrefPubMedGoogle Scholar
• 6 Quigley EM, Stanton C, Murphy EF. The gut microbiota and the liver. Pathophysiological and clinical implications. J Hepatol 2013; 58 (5) 1020-1027
  CrossrefPubMedGoogle Scholar
• 7 Giannelli V, Di Gregorio V, Iebba V , et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014; 20 (45) 16795-16810
  CrossrefPubMedGoogle Scholar
• 8 Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002; 68 (7) 3401-3407
  CrossrefPubMedGoogle Scholar
• 9 Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun 2013; 46: 66-73
  CrossrefPubMedGoogle Scholar
• 10 Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010; 28 (6) 737-744
  CrossrefPubMedGoogle Scholar
• 11 Terjung B, Söhne J, Lechtenberg B , et al. p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010; 59 (6) 808-816
  CrossrefPubMedGoogle Scholar
• 12 Chen Y, Yang F, Lu H , et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011; 54 (2) 562-572
  CrossrefPubMedGoogle Scholar
• 13 Wang Z, Klipfell E, Bennett BJ , et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472 (7341) 57-63
  CrossrefPubMedGoogle Scholar
• 14 Rutten NB, Rijkers GT, Meijssen CB , et al. Intestinal microbiota composition after antibiotic treatment in early life: the INCA study. BMC Pediatr 2015; 15: 204
  CrossrefPubMedGoogle Scholar
• 15 Martin R, Makino H, Cetinyurek Yavuz A , et al. Early-life events, including mode of delivery and type of feeding, siblings and gender, shape the developing gut microbiota. PLoS One 2016; 11 (6) e0158498
  CrossrefPubMedGoogle Scholar
• 16 Eckburg PB, Bik EM, Bernstein CN , et al. Diversity of the human intestinal microbial flora. Science 2005; 308 (5728) 1635-1638
  CrossrefPubMedGoogle Scholar
• 17 Rial SA, Karelis AD, Bergeron KF, Mounier C. Gut microbiota and metabolic health: the potential beneficial effects of a medium chain triglyceride diet in obese individuals. Nutrients 2016; 8 (5) E281
  CrossrefPubMedGoogle Scholar
• 18 Purohit V, Bode JC, Bode C , et al. Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 2008; 42 (5) 349-361
  CrossrefPubMedGoogle Scholar
• 19 Brandl K, Schnabl B. Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?. Expert Rev Gastroenterol Hepatol 2015; 9 (8) 1069-1076
  CrossrefPubMedGoogle Scholar
• 20 Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016; 13 (7) 412-425
  CrossrefPubMedGoogle Scholar
• 21 Yu J, Marsh S, Hu J, Feng W, Wu C. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract 2016; 2016: 2862173
  PubMedGoogle Scholar
• 22 Koenig JE, Spor A, Scalfone N , et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci U S A 2011; 108 (Suppl. 01) 4578-4585
  CrossrefPubMedGoogle Scholar
• 23 Bajaj JS, Heuman DM, Sanyal AJ , et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8 (4) e60042
  CrossrefPubMedGoogle Scholar
• 24 Bajaj JS, Hylemon PB, Ridlon JM , et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303 (6) G675-G685
  CrossrefPubMedGoogle Scholar
• 25 Dumas ME, Barton RH, Toye A , et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A 2006; 103 (33) 12511-12516
  CrossrefPubMedGoogle Scholar
• 26 Ponziani FR, Gerardi V, Pecere S , et al. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21 (43) 12322-12333
  CrossrefPubMedGoogle Scholar
• 27 Bajaj JS, Heuman DM, Hylemon PB , et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60 (5) 940-947
  CrossrefPubMedGoogle Scholar
• 28 Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291 (5505) 881-884
  CrossrefPubMedGoogle Scholar
• 29 Bäckhed F, Ding H, Wang T , et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101 (44) 15718-15723
  CrossrefPubMedGoogle Scholar
• 30 Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444 (7122) 1027-1031
  CrossrefPubMedGoogle Scholar
• 31 Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102 (31) 11070-11075
  CrossrefPubMedGoogle Scholar
• 32 Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol 2008; 49 (5) 821-830
  CrossrefPubMedGoogle Scholar
• 33 Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol 2009; 9 (5) 313-323
  CrossrefPubMedGoogle Scholar
• 34 Umesaki Y. Use of gnotobiotic mice to identify and characterize key microbes responsible for the development of the intestinal immune system. Proc Jpn Acad, Ser B, Phys Biol Sci 2014; 90 (9) 313-332
  CrossrefPubMedGoogle Scholar
• 35 Chung H, Pamp SJ, Hill JA , et al. Gut immune maturation depends on colonization with a host-specific microbiota. Cell 2012; 149 (7) 1578-1593
  CrossrefPubMedGoogle Scholar
• 36 Slack E, Hapfelmeier S, Stecher B , et al. Innate and adaptive immunity cooperate flexibly to maintain host-microbiota mutualism. Science 2009; 325 (5940) 617-620
  CrossrefPubMedGoogle Scholar
• 37 Usami M, Miyoshi M, Yamashita H. Gut microbiota and host metabolism in liver cirrhosis. World J Gastroenterol 2015; 21 (41) 11597-11608
  CrossrefPubMedGoogle Scholar
• 38 Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein Claudin-1 transcription. Dig Dis Sci 2012; 57 (12) 3126-3135
  CrossrefPubMedGoogle Scholar
• 39 Miyoshi M, Sakaki H, Usami M , et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clin Nutr 2011; 30 (2) 252-258
  CrossrefPubMedGoogle Scholar
• 40 Tabibian JH, Varghese C, LaRusso NF, O'Hara SP. The enteric microbiome in hepatobiliary health and disease. Liver Int 2016; 36 (4) 480-487
  CrossrefPubMedGoogle Scholar
• 41 Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev 2005; 29 (4) 625-651
  CrossrefPubMedGoogle Scholar
• 42 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146 (6) 1513-1524
  CrossrefPubMedGoogle Scholar
• 43 Neuschwander-Tetri BA, Loomba R, Sanyal AJ , et al; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385 (9972) 956-965
  CrossrefPubMedGoogle Scholar
• 44 Watanabe M, Houten SM, Mataki C , et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439 (7075) 484-489
  CrossrefPubMedGoogle Scholar
• 45 Hoefert B. Über die bakterienbefunde im duodenalsaft von gesunden und kranken. Zschr Klin Med 1921; 92: 221-235
  PubMedGoogle Scholar
• 46 Bellot P, Francés R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33 (1) 31-39
  CrossrefPubMedGoogle Scholar
• 47 Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res 2015; 39 (5) 763-775
  CrossrefPubMedGoogle Scholar
• 48 Ghoshal UC, Srivastava D, Ghoshal U, Misra A. Breath tests in the diagnosis of small intestinal bacterial overgrowth in patients with irritable bowel syndrome in comparison with quantitative upper gut aspirate culture. Eur J Gastroenterol Hepatol 2014; 26 (7) 753-760
  CrossrefPubMedGoogle Scholar
• 49 Yang CY, Chang CS, Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis, diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol 1998; 33 (8) 867-871
  CrossrefPubMedGoogle Scholar
• 50 Teltschik Z, Wiest R, Beisner J , et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. Hepatology 2012; 55 (4) 1154-1163
  CrossrefPubMedGoogle Scholar
• 51 Kwak DS, Jun DW, Seo JG , et al. Short-term probiotic therapy alleviates small intestinal bacterial overgrowth, but does not improve intestinal permeability in chronic liver disease. Eur J Gastroenterol Hepatol 2014; 26 (12) 1353-1359
  PubMedGoogle Scholar
• 52 Such J, Francés R, Muñoz C , et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002; 36 (1) 135-141
  CrossrefPubMedGoogle Scholar
• 53 Rai R, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy. J Clin Exp Hepatol 2015; 5 (Suppl. 01) S29-S36
  PubMedGoogle Scholar
• 54 Gómez-Hurtado I, Such J, Sanz Y, Francés R. Gut microbiota-related complications in cirrhosis. World J Gastroenterol 2014; 20 (42) 15624-15631
  CrossrefPubMedGoogle Scholar
• 55 Pérez-Paramo M, Muñoz J, Albillos A , et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31 (1) 43-48
  CrossrefPubMedGoogle Scholar
• 56 Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18 (2) 353-372
  CrossrefPubMedGoogle Scholar
• 57 Casafont F, Sánchez E, Martín L, Agüero J, Romero FP. Influence of malnutrition on the prevalence of bacterial translocation and spontaneous bacterial peritonitis in experimental cirrhosis in rats. Hepatology 1997; 25 (6) 1334-1337
  CrossrefPubMedGoogle Scholar
• 58 Fouts DE, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. J Hepatol 2012; 56 (6) 1283-1292
  CrossrefPubMedGoogle Scholar
• 59 Bunchorntavakul C, Chamroonkul N, Chavalitdhamrong D. Bacterial infections in cirrhosis: A critical review and practical guidance. World J Hepatol 2016; 8 (6) 307-321
  CrossrefPubMedGoogle Scholar
• 60 Berg RD. Bacterial translocation from the gastrointestinal tract. Trends Microbiol 1995; 3 (4) 149-154
  CrossrefPubMedGoogle Scholar
• 61 Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60 (1) 197-209
  CrossrefPubMedGoogle Scholar
• 62 Benten D, Wiest R. Gut microbiome and intestinal barrier failure--the “Achilles heel” in hepatology?. J Hepatol 2012; 56 (6) 1221-1223
  CrossrefPubMedGoogle Scholar
• 63 Cirera I, Bauer TM, Navasa M , et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34 (1) 32-37
  CrossrefPubMedGoogle Scholar
• 64 Francés R, González-Navajas JM, Zapater P , et al. Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis. Clin Exp Immunol 2007; 150 (2) 230-237
  CrossrefPubMedGoogle Scholar
• 65 Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010; 51 (4) 1327-1333
  CrossrefPubMedGoogle Scholar
• 66 Harputluoglu MM, Dertli R, Otlu B , et al. Nucleotide-binding oligomerization domain-containing protein 2 variants in patients with spontaneous bacterial peritonitis. Dig Dis Sci 2016; 61 (6) 1545-1552
  CrossrefPubMedGoogle Scholar
• 67 Rasaratnam B, Connelly N, Chin-Dusting J. Nitric oxide and the hyperdynamic circulation in cirrhosis: is there a role for selective intestinal decontamination?. Clin Sci (Lond) 2004; 107 (5) 425-434
  CrossrefPubMedGoogle Scholar
• 68 Terjung B, Spengler U. Atypical p-ANCA in PSC and AIH: a hint toward a “leaky gut”?. Clin Rev Allergy Immunol 2009; 36 (1) 40-51
  CrossrefPubMedGoogle Scholar
• 69 Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol 2013; 29 (3) 264-270
  CrossrefPubMedGoogle Scholar
• 70 Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002; 35 (3) 622-629
  CrossrefPubMedGoogle Scholar
• 71 Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, Triantos CK, Thomopoulos KC. Intestinal barrier dysfunction in cirrhosis: current concepts in pathophysiology and clinical implications. World J Hepatol 2015; 7 (17) 2058-2068
  CrossrefPubMedGoogle Scholar
• 72 Sipeki N, Antal-Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol 2014; 20 (10) 2564-2577
  CrossrefPubMedGoogle Scholar
• 73 Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016; 13 (2) 88-110
  CrossrefPubMedGoogle Scholar
• 74 Zhu Q, Zou L, Jagavelu K , et al. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol 2012; 56 (4) 893-899
  CrossrefPubMedGoogle Scholar
• 75 Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-163
  CrossrefPubMedGoogle Scholar
• 76 Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108 (1) 218-224
  CrossrefPubMedGoogle Scholar
• 77 Li Z, Yang S, Lin H , et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37 (2) 343-350
  CrossrefPubMedGoogle Scholar
• 78 Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54 (4) 556-563
  CrossrefPubMedGoogle Scholar
• 79 Park B, Lee HR, Lee YJ. Alcoholic liver disease: focus on prodromal gut health. J Dig Dis 2016; 17 (8) 493-500
  CrossrefPubMedGoogle Scholar
• 80 Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003; 139 (3) 186-193
  CrossrefPubMedGoogle Scholar
• 81 Albillos A, de la Hera A, González M , et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37 (1) 208-217
  CrossrefPubMedGoogle Scholar
• 82 Steib CJ, Hartmann AC, Hesler C , et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest 2010; 90 (7) 1024-1032
  CrossrefPubMedGoogle Scholar
• 83 Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol 2010; 22 (1) 28-33
  CrossrefPubMedGoogle Scholar
• 84 Ganz M, Csak T, Nath B, Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol 2011; 17 (43) 4772-4778
  CrossrefPubMedGoogle Scholar
• 85 Csak T, Ganz M, Pespisa J, Kodys K, Dolganiuc A, Szabo G. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells. Hepatology 2011; 54 (1) 133-144
  CrossrefPubMedGoogle Scholar
• 86 Arumugam M, Raes J, Pelletier E , et al; MetaHIT Consortium. Enterotypes of the human gut microbiome. Nature 2011; 473 (7346) 174-180
  CrossrefPubMedGoogle Scholar